Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppina Andreotti

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
International Journal of Molecular Sciences|December 6, 2016
The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense MutationsValentina Citro, Marco Cammisa, Ludovica Liguori, et al.
The Journal of Biological Chemistry|June 13, 2006
Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic alpha-helixGiuseppina Andreotti, Blanca López Méndez, Pietro Amodeo, et al.
Biochimie|March 8, 2024
Exploring ligand interactions with human phosphomannomutases using recombinant bacterial thermal shift assay and biochemical validationMaria Monticelli, Bruno Hay Mele, Demi Marie Wright, et al.
International Journal of Molecular Sciences|August 1, 2018
The Analysis of Variants in the General Population Reveals That <i>PMM2</i> Is Extremely Tolerant to Missense Mutations and That Diagnosis of PMM2-CDG Can Benefit from the Identification of ModifiersValentina Citro, Chiara Cimmaruta, Maria Monticelli, et al.
Orphanet Journal of Rare Diseases|October 19, 2011
Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro testsGiuseppina Andreotti, Valentina Citro, Agostina De Crescenzo, et al.
International Journal of Molecular Sciences|January 17, 2020
Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense MutationsLudovica Liguori, Maria Monticelli, Mariateresa Allocca, et al.
The Journal of Biological Chemistry|October 18, 2014
Conformational response to ligand binding in phosphomannomutase2: insights into inborn glycosylation disorderGiuseppina Andreotti, Israel Cabeza de Vaca, Angelita Poziello, et al.
International Journal of Molecular Sciences|March 11, 2023
Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its EfficacyIlaria Iacobucci, Bruno Hay Mele, Flora Cozzolino, et al.
Frontiers in Chemistry|October 24, 2017
Identification of Trombospondin-1 as a Novel Amelogenin Interactor by Functional ProteomicsAngela Capolupo, Chiara Cassiano, Agostino Casapullo, et al.
Cellular and Molecular Life Sciences : CMLS|November 30, 2017
D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFRGabriele Eden, Marco Archinti, Ralitsa Arnaudova, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
International Journal of Molecular Sciences|December 6, 2016
The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense MutationsValentina Citro, Marco Cammisa, Ludovica Liguori, et al.
The Journal of Biological Chemistry|June 13, 2006
Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic alpha-helixGiuseppina Andreotti, Blanca López Méndez, Pietro Amodeo, et al.
Biochimie|March 8, 2024
Exploring ligand interactions with human phosphomannomutases using recombinant bacterial thermal shift assay and biochemical validationMaria Monticelli, Bruno Hay Mele, Demi Marie Wright, et al.
International Journal of Molecular Sciences|August 1, 2018
The Analysis of Variants in the General Population Reveals That <i>PMM2</i> Is Extremely Tolerant to Missense Mutations and That Diagnosis of PMM2-CDG Can Benefit from the Identification of ModifiersValentina Citro, Chiara Cimmaruta, Maria Monticelli, et al.
Orphanet Journal of Rare Diseases|October 19, 2011
Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro testsGiuseppina Andreotti, Valentina Citro, Agostina De Crescenzo, et al.
International Journal of Molecular Sciences|January 17, 2020
Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense MutationsLudovica Liguori, Maria Monticelli, Mariateresa Allocca, et al.
The Journal of Biological Chemistry|October 18, 2014
Conformational response to ligand binding in phosphomannomutase2: insights into inborn glycosylation disorderGiuseppina Andreotti, Israel Cabeza de Vaca, Angelita Poziello, et al.
International Journal of Molecular Sciences|March 11, 2023
Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its EfficacyIlaria Iacobucci, Bruno Hay Mele, Flora Cozzolino, et al.
Frontiers in Chemistry|October 24, 2017
Identification of Trombospondin-1 as a Novel Amelogenin Interactor by Functional ProteomicsAngela Capolupo, Chiara Cassiano, Agostino Casapullo, et al.
Cellular and Molecular Life Sciences : CMLS|November 30, 2017
D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFRGabriele Eden, Marco Archinti, Ralitsa Arnaudova, et al.
Pageof 6